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Summary 
Introduction 
Description of technology 
Corneal implants are small segments of rings or full rings of synthetic mate-
rial that are implanted in the corneal stroma to achieve flattening of the sur-
face. In contrast to corneal transplantation that is the most frequent used 
treatment for ectatic corneal disorders in later stages, corneal implants is a 
less invasive and reversible intervention.  
In this report we analyse whether corneal implants are more or equally effec-
tive and safer than corneal transplantation or no intervention. 
Health problem 
Originally, intrastromal corneal implants were developed for the treatment 
of myopia. Later, the implants were also considered for the correction of ec-
tatic corneal disorders such as keratoconus and post-LASIK corneal ectasia. 
Keratoconus is a non-inflammatory corneal ectasia, characterised by a pro-
gressive increase in corneal curvature and thinning of the cornea. Eventually, 
an obvious cone-shaped protrusion of the corneal surface may develop. 
Corneal ectasia is a rare, but serious complication after LASIK (Laser-assisted 
in situ keratomileusis). The condition is similar to keratoconus where the cor-
nea starts to bulge forwards at a variable time after LASIK. 
 
Methods 
Answering the research questions regarding efficacy and safety-related out-
comes was based on a systematic literature from different databases. The study 
selection, data extraction and assessing the methodological quality of the stud-
ies was performed by two review authors (SF, IZ), independently from each 
other. 
Domain effectiveness 
The following efficacy-related outcomes were used as evidence to derive a 
recommendation: length of hospital stay (or time to resume work/normal ac-
tivities), re-operation rate and change of visual acuity (change of two or more 
Snellen lines). 
Domain safety 
The following safety-related outcomes were used as evidence to derive a rec-
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Results 
Available evidence 
We could not identify any controlled trials comparing intrastromal corneal 
implants with either corneal transplantation or no intervention for the treat-
ment of keratoconus or post-LASIK corneal ectasia. Therefore, we included 
uncontrolled studies (single-arm studies) with at least 50 eyes for assessing 
efficacy and safety.  
In total, 5 single-arm studies with 627 eyes met our inclusion criteria. The 
mean age of patients was 26-37 years and the majority were males.  
Clinical effectiveness 
Clinically relevant improvement of visual acuity (two or more Snellen lines), 
occurred in more treated eyes than a worsening of visual acuity (e.g., UCVA 
improved in 79% and worsened in 0% of the treated eyes). The change from 
baseline was also considered as statistically significant. 
According to the available data, between 4 and 23% of the eyes with an im-
planted intrastromal corneal ring had to be re-operated. Length of hospital 
was not reported in any of the identified studies. 
Safety 
Intra-operative adverse events, like difficulties in forming the intrastromal 
tunnel to implant the rings or anterior perforation, occurred in 0-2% of the 
eyes. Post-operative adverse events occurred in 2 to 23% of the treated eyes. 
Upcoming evidence 
Currently, there are no registered ongoing or planned controlled trials com-
paring intrastromal corneal implants with corneal transplantation for a treat-
ment of keratoconus or post-LASIK ectasia. 
Reimbursement 
Currently, the use of intrastromal corneal implants for the treatment of ker-
atoconus or post-LASIK corneal ectasia is not reimbursed by the Austrian 
health care system. 
 
Discussion 
Overall, the strength of evidence for efficacy and safety is low to very low. 
Naturally, this is mainly due to the study design of the single-arm studies. 
Considering the findings of the included single-arm studies regarding clini-
cal effectiveness, it seems that the implantation of intrastromal corneal im-
plants can improve visual acuity in a clinically relevant manner. Moreover, a 
treatment of keratoconus as well as post-LASIK corneal ectasia with intra-
stromal corneal implants seems relatively safe. 
Nevertheless, due to a lack of controlled trials we are not able to draw any 
conclusions on the clinical effectiveness of intrastromal corneal implants for 
a treatment of keratoconus or post-LASIK ectasia compared to corneal trans-
plantation or even no intervention. 
A major strength of intrastromal corneal implants is their reversibility. Fur-
thermore, after implantation no immunosuppressive drugs are needed, like 
after corneal transplantation. 
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Conclusion 
The current evidence is not sufficient to prove that intrastromal corneal im-
plants are equally or more effective and safe than corneal transplantation or 
no intervention for treatingf keratoconus or post-LASIK corneal ectasia. 
However, the comparison before and after the ring implantations of the sin-
gle-arm studies have shown that the visual acuity has improved and that im-
provement has been clinically relevant in a large proportion of patients. Fur-
thermore, the implantation of intrastromal corneal rings seems to be rela-
tively safe and adverse events were minor. 
The inclusion in the catalogue of benefits is recommended with restrictions. 
  
kein Beweis, dass Ringe 
wirksamer und sicherer 
als Transplantation 
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Einschränkungen 
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Zusammenfassung 
Einleitung 
Beschreibung der Technologie 
Korneale Ringimplantate sind entweder volle Ringe oder Ringsegmente aus 
Kunststoff, die in das korneale Stroma eingebracht werden, um die Oberflä-
che zu glätten. Die Implantation erfolgt durch Tunnel, die mechanisch oder 
durch einen Laser erzeugt werden. 
Derzeit gibt es fünf Hersteller der Implantate, die alle ein CE-Zertifikat  
haben: 
 Bisantis Segments (Optikon 2000 SpA und Soleko SpA)1, 
 Ferrara RingTM (gehört zu AJL OPHTHALMIC S.A.), 
 Intacs® (gehört zu AJL OPHTHALMIC S.A.), 
 Keraring-Intrastromal corneal ring (Mediphacos), 
 MyoRing® (DIOPTEX). 
Der Hauptunterschied zwischen den Produkten liegt in deren Beschaffenheit 
mit verschiedenen Dicken und Durchmessern. Während fast alle Produkte 
sogenannte Ringsegmente sind, ist der MyoRing® ein voller Ring. 
Intrakorneale Ringimplantate haben zum Ziel die Sehschärfe zu verbessern. 
Im Vergleich zur Hornhauttransplantation, die vor allem im späteren Krank-
heitsstadium am häufigsten bei der Behandlung von Keratokonus oder Ke-
ratektasie nach LASIK eingesetzt wird, sind korneale Ringimplantate eine 
weniger invasive, risikoärmere (z. B. keine Immunsuppressiva nötig) und re-
versible Technologie. Ein weiterer Vorteil im Vergleich zur Transplantation 
ist die Möglichkeit einer nachträglichen Adjustierung und die geringere War-
tezeit (keine SpenderInnen nötig).  
Der Bericht behandelt die Frage, ob die Behandlung von Keratokonus oder 
Keratektasie nach LASIK mittels intrakornealer Ringimplantate wirksamer 
und sicherer als (oder zumindest genauso wirksam und sicher wie) die Horn-
hauttransplantation oder keine Intervention ist. 
Indikation und therapeutisches Ziel 
Ursprünglich wurden intrakorneale Ringimplantate für die Behandlung der 
Kurzsichtigkeit entwickelt. Erst später wurden die Implantate auch für die 
Behandlung ektatischer Hornhauterkrankungen in Betracht gezogen. 
Der vorliegende Bericht beschränkt sich hierbei auf die Behandlung des Ke-
ratokonus und der Keratektasie nach LASIK (Laser-in-situ-Keratomileusis). 
Der Keratokonus ist eine nicht-entzündliche Hornhauterkrankung, die sich 
in einer verstärkten Krümmung und gleichzeitiger Ausdünnung der Horn-
haut des Auges manifestiert. Die Krankheit tritt oftmals bereits im Jugend-
alter auf. Die Keratektasie ist eine seltene Komplikation der LASIK, oftmals 
manifestiert durch Kurzsichtigkeit, und eine Hornhautverkrümmung. 
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Die Entstehung des Keratokonus ist weitestgehend unklar. Es gilt ein Zu-
sammenhang mit systemischen Erkrankungen (z. B. Trisomie 21) als wahr-
scheinlich. Oxidativer Stress, aber auch das Reiben der Augen können die 
Krankheit weiter verschlimmern. 
Für die Keratektasie nach LASIK gibt es mehrere Risikofaktoren: z. B. ab-
normale präoperative Topografie des Auges, geringe Dicke der Hornhaut oder 
starke Kurzsichtigkeit. 
Auch wenn sowohl Keratokonus, als auch post-LASIK Keratektasie selten 
sind (Prävalenz weniger als 5 pro 10.000 Menschen) und die Konsequenzen 
für die Gesellschaft eher gering, so führen beide Krankheiten zu erheblichen 
Seheinschränkungen und damit auch Einschränkungen in der Lebensquali-
tät der Betroffenen. 
Für die Behandlung von Keratokonus und Keratektasie nach LASIK stehen 
die gleichen Interventionen zu Verfügung: in frühen Stadien werden weiche 
Kontaktlinsen oder eine Brille eingesetzt, während in mittleren Stadien be-
reits formstabile Kontaktlinsen zum Einsatz kommen. In späteren Stadien ist 
ein Tragen von Kontaktlinsen oder Brillen nicht mehr ausreichend und inva-
sive Eingriffe werden notwendig. Dazu zählen die korneale Transplantation, 
aber auch intrakorneale Ringimplantate und die sogenannte Vernetzungsbe-
handlung (Collagen Cross-Linking). 
Jedoch setzt die Behandlung des Keratokonus sowie der Keratektasie nach 
LASIK mittels intrakornealer Ringimplantate vor allem eine gewisse Dicke 
der Hornhaut (abhängig vom Produkt) und eine Kontaktlinsenunverträglich-
keit der PatientInnen voraus. 
 
Methodik 
Die Beantwortung der Forschungsfragen bezüglich Wirksamkeit und Sicher-
heit basierte auf einer systematischen Literatursuche in folgenden Daten-
banken: 
 Medline via Ovid, 
 Embase, 
 the Cochrane Library, 
 CRD (DARE, NHS-EED, HTA).  
Zusätzlich wurde noch eine Handsuche durchgeführt und es gab eine Anfrage 
nach Studien bei den einzelnen Herstellern. 
Die Studienauswahl erfolgte nach dem 4-Augenprinzip durch den Erstautor 
(SF) und den Drittautor (EC). Der Erstautor (SF) extrahierte die Studien-
daten und die Zweitautorin (IZ) kontrollierte die Daten. 
Die Daten der für die Entscheidung herangezogenen Endpunkte wurden aus 
den einzelnen Studien zusammengefasst und nach GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) bewertet.  
Zusätzlich wurde das Bias-Risiko für jeden entscheidungsrelevanten End-
punkt nach einer Checkliste von zwei AutorInnen (SF, IZ), unabhängig von 
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Klinische Wirksamkeit 
Zur Bewertung der Wirksamkeit intrakornealer Ringimplantate wurden die 
folgenden entscheidenden Endpunkte für eine Empfehlung herangezogen: 
 Krankenhausaufenthalt (oder Zeit bis Wiederaufnahme  
Arbeitstätigkeit/normale Tätigkeiten) 
 Reoperationsrate 
 Änderung Sehschärfe (Änderung von zwei oder mehr Snellen-Linien) 
Sicherheit 
Zur Bewertung der Sicherheit intrakornealer Ringimplantate wurden die 
folgenden entscheidenden Endpunkte für eine Empfehlung herangezogen: 
 intraoperative unerwünschte Ereignisse 




Es konnten keine kontrollierten Studien identifiziert werden, die eine Be-
handlung des Keratokonus oder der Keratektasie nach LASIK mittels intra-
kornealer Ringimplantate mit einer Hornhauttransplantation oder keiner In-
tervention verglichen. Daher wurden unkontrollierte Beobachtungsstudien 
(sogenannte Ein-Arm-Studien) mit 50 Augen oder mehr eingeschlossen. 
Insgesamt 5 Ein-Arm-Studien mit 627 Augen entsprachen den Einschluss-
kriterien. Das Durchschnittsalter der PatientInnen lag zwischen 26 und 37 
Jahren mit einem Anteil an Frauen von 30-50 %. Die Nachbetrachtungszeit 
der meisten Studien lag bei 12 Monaten, wobei es auch jeweils eine Studie 
mit 24 und 96 Monaten (entspricht 8 Jahren) Nachbetrachtungszeit gab. Die 
Studien untersuchten (fast) ausschließlich die Behandlung von Keratokonus 
In allen Studien wurde Intacs® implantiert, wobei in zwei Studien auch Ke-
raring implantiert wurden. 
Es konnten keine Studien identifiziert werden, die andere Produkte (z. B. Fer-
rara RingTM, MyoRing®) oder die Behandlung von Keratektasie nach LASIK 
untersuchten.  
Klinische Wirksamkeit 
Die Änderung der Sehschärfe wurde in vier Studien berichtet (eine oder mehr 
Snellen-Linien). So konnte z. B. die unkorrigierte Sehschärfe nach 12 Mona-
ten in 70-80 % der Augen verbessert werden. Eine Verschlechterung trat in 
weniger als 10 % der Augen auf.  
Für Empfehlung der Aufnahme der Leistung, wurde lediglich der Endpunkt 
„Änderung der Sehschärfe“ von 2 oder mehr Snellen-Linien für eine Ent-
scheidung herangezogen (berichtet in 2 Studien). Denn erst eine Änderung 
von 2 Snellen-Linien gilt als klinisch relevant: 
So konnte z. B. die unkorrigierte Sehschärfe nach 6 Monaten in 79 % der Au-
gen um 2 oder mehr Snellen-Linien verbessert werden, während es bei keinen 
der behandelten Augen eine Verschlechterung gab. Nach 12 Monaten konnte 
die korrigierte Sehschärfe in 42 % verbessert werden. Eine Verschlechterung 
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Die Reoperationsrate lag bei 4-23 %. Ein direkter Vergleich mit der Horn-
hauttransplantation oder keiner Behandlung lag nicht vor. 
Die Dauer des Krankenhausaufenthalts (oder Zeit bis Wiederaufnahme Ar-
beitstätigkeit/normale Tätigkeiten) wurde in keiner der Studien berichtet. 
Sicherheit 
Während der Operation traten in 0-2 % der behandelten Augen Komplikati-
onen auf: z. B. Schwierigkeiten bei der Formung der Tunnel zur Implantation 
der Ringe. Nach dem operativen Eingriff gab es in 2 bis 23 % der Augen un-
erwünschte Ereignisse, wie Wanderung des Implantats, Infektion oder Per-
foration der Hornhaut. 
Laufende Studien 
Aktuell sind keine laufenden kontrollierten Studien registriert, die die Be-
handlung ektatischer Hornhauterkrankungen mittels intrakornealer Ringim-
plantate mit einer Hornhauttransplantation vergleichen. 
Zwei registrierte randomisierte kontrollierte Studien vergleichen verschiedene 
intrakorneale Ringimplantate bei Keratokonus miteinander (siehe Appendix). 
Kostenerstattung 
Derzeit werden in Österreich die Kosten für den Einsatz intrakornealer Ringe 
bei der Behandlung ektatischer Hornhauterkrankungen nicht separat erstattet. 
 
Diskussion 
Ziel des Berichts war es die Wirksamkeit und Sicherheit intrakornealer Ring-
implantate bei der Behandlung von Keratokonus oder Keratektasie nach LA-
SIK im Vergleich zu einer Hornhauttransplantation oder keiner Intervention 
zu untersuchen.  
Nachdem keine kontrollierten Studien identifiziert wurden, wurden 5 Ein-
Arm-Studien für die Bewertung herangezogen. Aufgrund des unkontrollierten 
Studiendesigns ist die Stärke der Evidenz jedoch nur gering bis sehr gering. 
Auch wenn die Studienlage nicht eindeutig die Wirksamkeit und Sicherheit 
der kornealen Ringimplantate belegen kann, so gibt es immerhin Anzeichen, 
dass eine Verbesserung der Sehschärfe erreicht werden kann – auch wenn es 
durchaus bei einigen Augen eine Verschlechterung der Sehschärfe gab. 
Ein entscheidender Vorteil der Implantate ist deren Reversibilität. Die not-
wendigen Reoperationen konnten ohne bleibende Schäden durchgeführt wer-
den. Außerdem sind nach dem Eingriff keine Immunsuppressiva nötig, wie 
es bei der Hornhauttransplantation der Fall ist und der Eingriff ist weniger 
invasiv als eine Hornhauttransplantation. 
Nicht zuletzt scheinen die Implantate – zumindest kurzfristig gesehen – re-
lativ sicher. 
Kritikpunkte der Studien sind vor allem die relativ kurzen Nachbeobach-
tungszeiträume in der Mehrzahl der Studien, nicht berichtete PatientInnen-
eigenschaften in einigen Studien (z. B. Alter), die Tatsache, dass nicht alle 
Studien Rückschlüsse auf eine klinisch relevante Änderung der Sehschärfe 
zuließen und in zwei Studien war der Erstautor Berater bei einem der Her-






während OP:  
in 0-2 % Augen 
Komplikationen nach OP: 
in 2-23 % Augen 
keine laufenden Studien 
Kontrollgruppe 
Hornhauttransplantation 
zwei RCTs vergleichen 
Implantate miteinander 
Einsatz Ringe in 
Österreich derzeit  
nicht erstattet 











Implantate relativ sicher 
einige Kritikpunkte  
der Studien 
Intrastromal corneal implants for ectatic corneal disorders 
14 LBI-HTA | 2015 
Entscheidende Schwächen des vorliegenden Berichts sind insbesondere: der 
konsequente Ausschluss von Studien, die weniger als 50 Augen untersuchten, 
der Ausschluss von Studien die retrospektiv angelegt waren (dazu zählten 
auch Studien mit einer historischen Kontrollgruppe) und bei zwei der ein-
geschlossenen Studien war nicht eindeutig klar, ob diese prospektiv durch-
geführt wurden. 
Ein generelles Problem ist, dass Keratokonus und Keratektasie nach LASIK 
seltene Erkrankungen sind. Dies bedingt geringe PatientInnenzahlen und ge-
staltet es durchaus schwierig, prospektive kontrollierte Studien durchzufüh-
ren. Zudem ist die Wahl der Hornhauttransplantation als Vergleichsinter-
vention kritisch, da einer Behandlungsgruppe der weniger invasive Eingriff 
der intrakornealen Ringimplantate vorenthalten würde.  
Ungeachtet der etwaigen, oben genannten, Schwierigkeiten, wurden bei der 
Literatursuche zwei Abstracts von randomisierten kontrollierten Studien iden-
tifiziert, die die Behandlung des Keratokonus durch intrakorneale Ringim-
plantate mit der Hornhauttransplantation verglichen. Jedoch wurden die Er-
gebnisse der beiden Studien scheinbar nie veröffentlicht. 
 
Empfehlung  
Die gegenwärtige Studienlage lässt keine Rückschlüsse zu, ob eine Behand-
lung des Keratokonus oder Keratektasie nach LASIK mittels intrakornealer 
Ringimplantate wirksamer oder sicherer als andere Alternativen ist.  
Ein Vergleich der Sehschärfe vor und nach der Implantation lässt vermuten, 
dass die Sehschärfe durchaus verbessert werden kann. Außerdem scheinen 
die Implantate relativ sicher. Aufgrund der geringeren Invasivität und Re-
versibilität ist die Ringimplantation jedenfalls vor einer Hornhauttransplan-
tation in Betracht zu ziehen. 
Aus den oben genannten Gründen wird daher eine Aufnahme in den Katalog 
medizinischer Einzelleistung empfohlen – jedoch unter folgenden Einschrän-
kungen: 
 Es besteht eine Kontaktlinsenunverträglichkeit oder eine 
Behandlung mit Kontaktlinsen ist nicht (mehr) möglich 
 Die individuellen Indikationen und Kontra-Indikationen der 
einzelnen Produkte müssen beachtet werden. 
 Die Leistung sollte nur in größeren Krankenhäusern  
(z. B. Universitätskliniken) durchgeführt werden. 
 Die Sicherheit der Implantate sollte in einer nationalen Datenbank 
dokumentiert und überwacht werden. 
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1 Scope 
1.1 Research question 
Are intrastromal corneal implants (rings/ring segments) in comparison to 
corneal transplants (or no intervention) in patients with keratoconus or post-
LASIK2 iatrogenic corneal ectasia equally or more effective and safe concern-
ing length of hospital stay (or time to work resumption), quality of life, re-
operation rate, patient satisfaction, change of visual acuity and adverse events? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarised in Table 1.2-1. 
Table 1.2-1: Inclusion criteria 
Population  Patients with: 
 Keratoconus (ICD-10 code: H18.6) [1] 
 who are not able to wear glasses or contact lenses (due to intolerance) or  
 who show an unsatisfactory visual acuity with glasses or contact lenses 
 Post-LASIK3 iatrogenic corneal ectasia (ICD-10 code: Q13.4), 
 MeSH-terms: C11 Eye Diseases, C11.204 Corneal Diseases, C11.204.627 Keratoconus [1] 
Intervention  Intracorneal ring segments (ICRS) or intracorneal rings or intrastromal corneal 
rings or intrastromal corneal implants 
 Product names: Ferrara RingTM (Ferrara OphthalmicsTM)  
Intacs® (Addition TechnologyTM), Keraring (Mediphacos), MyoRing® (DIOPTEX),  
[Bisantis Segments (Optikon), probably not available anymore] 
 MeSH-terms: E07.695 Prostheses and Implants, E07.695.225 Eye, Artificial 
Control  Corneal transplantation 
 No intervention4 
Outcomes  
Efficacy  Length of hospital stay (or time to work resumption) 
 Quality of life (health- or vision-related) 
 Re-operation rate 
 Patient satisfaction 
 Change of visual acuity 
Safety  Adverse events (intra- and post-operative) 
 
                                                             
2 Laser-assisted in situ keratomileusis 
3 Laser-assisted in situ keratomileusis 
4 In addition, “no intervention” was considered as comparator. This decision was made, 
just in case there are no appropriate controlled trials. 
PIKO-Frage 
Einschlusskriterien 
Intrastromal corneal implants for ectatic corneal disorders 
16 LBI-HTA | 2015 
Study design  
Efficacy  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 Prospective single-arm studies (with 50 and more eyes)5 
Safety  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 Prospective single-arm studies (with 50 and more eyes) 
 
 
1.3 Literature search 
The systematic literature search was conducted on the 29th of December 2014 
in the following databases:  
 Medline via Ovid 
 Embase 
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
In addition, these websites were searched for relevant assessments on the 12th 
of January 2015 (without any hits): 
 Canadian Agency for Drugs and Technologies in Health 
(http://www.cadth.ca/index.php/en/home)  
 NIHR Health Technology Assessment Programme 
(http://www.hta.ac.uk/) 
 NHS Institute for Health and Clinical Excellence 
(http://www.nice.org.uk/) 
 WHO Health Evidence Network 
(http://www.euro.who.int/en/what-we-do/data-and-evidence) 
The systematic search was limited to clinical trials in Medline and Embase. 
After deduplication, 201 citations were available. The specific search strate-
gy employed can be found in the Appendix.  
A total of 167 new citations were identified through studies sent by the manu-
facturers. 
By hand search (internet and Scopus), 61 additional citations were found, re-




                                                             
5 Single-arm studies are only considered for assessing the clinical effectiveness when 
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1.4 Flow chart study of selection 
Overall, 429 hits were identified. The references were screened by two inde-
pendent researchers (SF, CE) and in case of disagreement a third researcher 
was involved to solve the differences. The selection process is displayed in 
Figure 1.4-1. Articles that were excluded due to several reasons but still used 
as background are categorised under “background literature”. Furthermore, 
we were not able to order five articles. These are categorised under “not avail-
able”. 
 
Figure 1.4-1: Flow chart of study selection (PRISMA Flow Diagram) 
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2 Description and technical 
characteristics of technology 
2.1 Methods 
Research questions 
Element ID Research question 
Importance 
2 = critical 
1 = optional 
B0001 What are intrastromal corneal implants and the comparators? 2 
B0002 What is the claimed benefit of intrastromal corneal implants in relation 
to the comparators? 
2 
B0003 What is the phase of development and implementation of intrastromal 
corneal implants and the comparators? 
1 
B0004 Who administers intrastromal corneal implants and the comparators 
and in what context and level of care are they provided? 
2 
B0008 What kind of special premises are needed to use intrastromal corneal 
implants and the comparators? 
2 
B0009 What supplies are needed to use intrastromal corneal implants and  
the comparators? 
2 
A0020 For which indications have intrastromal corneal implants received 
marketing authorisation or CE marking? 
1 
A0021 What is the reimbursement status of intrastromal corneal implants? 1 
 
Sources 
To answer the research questions regarding the description and technical 
characteristics of the technology, the results from the systematic literature 
search (see Chapter 1.3) in Medline via Ovid, Embase, the Cochrane Library 
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2.2 Results 
Features of the technology and comparators 
B0001 – What are intrastromal corneal implants and the comparators? 
Corneal implants are small segments of rings or full rings of synthetic mate-
rial (e.g., polymethyl methacrylate or acrylic polymers) that are implanted in 
the corneal stroma to achieve flattening of the surface. The rings are implant-
ed in channels created mechanically or by means of a laser [2, 3]. 
Currently, five products of intrastromal corneal implants are marketed by five 
manufacturers [2, 3]: 
 Bisantis Segments (Optikon 2000 SpA and Soleko SpA, Italy)6, 
 Ferrara RingTM (former Ferrara OphthalmicsTM, Brazil, belongs  
now to AJL OPHTHALMIC S.A., Spain)7, 
 Intacs® (former Addition TechnologyTM, USA, belongs now to  
AJL OPHTHALMIC S.A., Spain)8, 
 Keraring-Intrastromal corneal ring (Mediphacos, Brazil)9, 
 MyoRing® (DIOPTEX, Austria)10. 
The main difference between these products is their design (full rings or seg-
ments) with different shapes, diameters and thicknesses [3]. Bisantis Seg-
ments, Ferrara RingTM, Intacs® and Keraring are arc segments and therefore 
called intracorneal ring segments (ICRS). The MyoRing® is a full ring and 
therefore called a corneal intrastromal implantation system (CISIS). In the 
following, “rings” is used to designate both full rings and ring segments. 
Generally, optical corrections, such as contact lenses (used in early stages of 
keratoconus) and corneal transplantation, are treatment options for ectatic 
corneal disorders [4, 5]. Collagen cross-linking is a relatively new treatment 
option that is supposed to slow the progression of the disease [5, 6]. However, 
intrastromal corneal implants are indicated when patients show contact lens 
intolerance (preferably in the absence of corneal disorders) [4].  
Corneal transplantation has been used for many decades to treat ectatic cor-
neal disorders and is the most frequent used treatment for ectatic corneal dis-
orders [5, 6]. Furthermore, in the description of the application form we re-
ceived from the Austrian Ministry of Health (“Verwaltung von Änderungs- 
und Ergänzungsvorschlägen zum Leistungskatalog des BMG”, VAEV) the 
only treatment alternative that is mentioned is corneal transplantation. In 
addition, several papers defined intrastromal corneal implants as an alterna-
tive to keratoplasty [7]. Thus, corneal transplantation was exclusively chosen 
as a comparator, even though it is more invasive than the use of intrastromal 
corneal implants [4, 8]. 
                                                             
  6 It seems very likely that this product is not available anymore, since the manufac-
turer‘s website could not be identified (access date: 20th January 2015). 
  7 See also http://www.ferrararing.com.br/en/products and http://www.ajlsa.com 
  8 See also http://www.additiontechnology.com and http://www.ajlsa.com 
  9 See also http://www.mediphacos.com/en/medico/produtos/ 




fünf Hersteller von 
Implantaten 
Implantate 







Description and technical characteristics of technology 
LBI-HTA | 2015 21 
Corneal transplantation, also known as corneal grafting, consists in the re-
placement of the diseased cornea by corneal tissues from a suitable, deceased 
donor. There are several methods of transplantations: e.g., penetrating kera-
toplasty (PKP) designates the transplantation of the entire corneal tissue, deep 
anterior lamellar keratoplasty (DALK) the transplantation of the anterior cor-
neal layers while preserving Descement’s membrane and endothelium [4, 5]. 
In addition, “no intervention” was considered as a secondary comparator be-
sides corneal transplantation.  
 
B0002 – What is the claimed benefit of  
intrastromal corneal implants in relation to the comparators? 
Intrastromal corneal implants for the treatment of keratoconus and post-
LASIK corneal ectasia are intended to improve visual acuity – like corneal 
transplantation as well [4, 9]. 
The main expected advantage of intrastromal corneal implants over other 
surgical interventions like corneal transplantation is that the implants can 
be removed relatively easily. This allows a (partial) reversal of the correction 
or the replacement with different rings to further adapt the needed correc-
tion [5, 10]. 
Furthermore, the intervention is a minimally invasive surgical option. Thus, 
a possibly resulting strength is that patients are allowed to quickly resume 
work or normal activities, as compared to corneal transplantation [3, 10]. 
A major issue of corneal transplantation is that an adequate donor is required. 
This implicates waiting times, the matching of human leukocyte antigen 
(HLA), the use of immunosuppressive drugs (even only local), the life expec-
tancy of the transplant (approximately ten years) and a more complicated re-
operation [4-6, 8]. 
Since corneal transplantation is a more invasive intervention, it entails higher 
intra-operative and post-operative risks as well as higher risks for secondary 
trauma due to a weakening of the structure of the eye ball [4-6, 8]. 
 
B0003 – What is the phase of development and  
implementation of intrastromal corneal implants and the comparators? 
Since the early 1990s for myopia and since 2004 for ectatic corneal disorders, 
intrastromal corneal implants have been sold and in use. Thus, the device is 
not in a phase of development anymore and – more or less –fully developed. 
Similarly, corneal transplantation has already been in use for many decades 
and is a well-established technique [2, 4]. 
 
Administration, investments, personnel and  
tools required to use the technology and the comparator(s) 
B0004 – Who administers intrastromal corneal implants and the 
comparators and in what context and level of care are they provided? 
The implantation of intrastromal corneal implants should be performed by 
an eye surgeon (or corneal surgeon) with the support of two persons of the 
nursing staff. The procedure can be done under topical or general anaesthet-
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For the corneal transplantation, general anaesthesia or local anaesthesia and 
a sedative are needed. The operation itself requires a corneal surgeon with a 
supporting team. It can be performed in an inpatient setting or in an outpa-
tient facility [4]. 
 
B0008 – What kind of special premises are needed  
to use intrastromal corneal implants and the comparators? 
See Element ID B0009. 
 
B0009 – What supplies are needed to use intrastromal corneal implants 
and the comparators? 
For intrastromal corneal implants as well as corneal transplantation a sterile 
operation theatre is suggested [4, 10]. However, since for inserting intrastro-
mal corneal implants the eye ball needs not to be opened, the operation can 
also performed in a “Behandlungsraum-invasiv” [11]. 
In addition, for the implantation of intrastromal corneal implants, a channel 
has to be created to insert the device. This can be done with a femtosecond 
laser or mechanically; thus, several instruments are needed for the interven-
tion (e.g., a Sinsky hook, a knife, etc.) [2]. 
Several instruments are likewise required for corneal transplantation, as is a 
transplant from an adequate donor (requiring a donor management system, 
immunosuppressive drugs, etc.) [5]. 
 
Regulatory & reimbursement status  
A0020 – For which indications have intrastromal corneal implants 
received marketing authorisation or CE marking? 
Initially, intrastromal corneal implants were developed for the treatment of 
myopia and several products received market authorisation in Europe (CE 
marking) for this indication. However, at the same time another intervention 
for this disease arose and overshadowed intrastromal corneal rings: laser-as-
sisted in situ keratomileusis (LASIK). Therefore, intrastromal corneal im-
plants never achieved commercial success for the treatment of myopia [3].  
In addition, intrastromal corneal implants were also considered to be a ther-
apeutic alternative for the correction of ectatic corneal disorders such as ker-
atoconus and post-LASIK corneal ectasia [3]. 
Thereafter, all products of intrastromal corneal implants mentioned at the 
beginning of Chapter 2.2 that are actually available are approved by the Com-
munauté Européenne (CE) for the treatment of keratoconus (and post-LASIK 
ectasia). Intacs® is also approved by the US FDA –however, as a Humanitar-
ian Use Device (HUD)11. 
An overview of the different intrastromal corneal ring products based on the 
information of the manufacturers’ websites is listed in the table below. 
                                                             
11 An HUD is a device that is intended to benefit patients by treating or diagnosing a 
disease or condition that affects or is manifested in fewer than 4,000 individuals in 
the United States per year. 
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Table 2.2-1: Overview of marketing authorisation of intrastromal corneal rings for keratoconus 
Manufacturer FDA-approval CE-marking 
Bisantis Segments  





Ferrara RingTM (Ferrara OphthalmicsTM, Brazil) No Yes 
Intacs® (Addition TechnologyTM, USA) Yes Yes 
Keraring – Intrastromal corneal ring (Mediphacos) No Yes 
MyoRing® (DIOPTEX) No Yes 
References: individual manufacturers’ websites 
 
A0021 – What is the reimbursement status of  
intrastromal corneal implants? 
Actually, the use of intrastromal corneal implants for the treatment of kera-
toconus or post-LASIK corneal ectasia is not included in the Austrian hospi-
tal benefit catalogue. Therefore, the intervention itself is not reimbursed by 
the Austrian health care system. 
 
 
                                                             
12 Since we could not identify the website of the manufacturer, we were not able to 
find any information regarding FDA and CE approval. 
Einsatz Ringe in 
Österreich derzeit  
nicht erstattet 
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3 Health problem and current use 
3.1 Methods 
Research questions 
Element ID Research question 
Importance 
2 = critical 
1 = optional 
A0001 For which health conditions, and for what purposes is intrastromal 
corneal implants used? 
2 
A0002 What is the disease or health condition in the scope of this assessment?  2 
A0003 What are the known risk factors for keratoconus or post-LASIK corneal 
ectasia? 
2 
A0004 What is the natural course of keratoconus or post-LASIK corneal ectasia? 2 
A0005 What is the burden of keratoconus or post-LASIK corneal ectasia? 2 
A0006 What are the consequences of keratoconus or post-LASIK corneal 
ectasia for society? 
2 
A0024 How is keratoconus or post-LASIK corneal ectasia currently diagnosed 
according to published guidelines and in practice? 
2 
A0025 How is keratoconus or post-LASIK corneal ectasia currently managed 
according to published guidelines and in practice? 
2 
A0007 What is the target population in this assessment? 2 
A0023 How many people belong to the target population? 1 
A0011 How much is intrastromal corneal implants utilised? 2 
 
Sources 
To answer the research questions regarding the health problem and current 
use, the results from the systematic literature search (see Chapter 1.3) in 
Medline via Ovid, Embase, the Cochrane Library plus CRD (DARE, NHS-
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3.2 Results 
A0001 – For which health conditions, and  
for what purposes are intrastromal corneal implants used? 
Originally, intrastromal corneal rings were developed for the treatment of 
myopia. Later, intrastromal corneal implants were also considered for the 
correction of ectatic corneal disorders such as keratoconus and post-LASIK 
corneal ectasia [3, 7]. 
 
A0002 – What is the disease or health condition in the scope  
of this assessment?  
Based on the information given in the VAEV (see also Chapter2.2), this sys-
tematic review will exclusively focus on the treatment of keratoconus and post-
LASIK corneal ectasia. 
Keratoconus is a non-inflammatory corneal ectasia, characterised by a progres-
sive increase in corneal curvature and thinning of the cornea. Eventually, an 
obvious cone-shaped protrusion of the corneal surface may develop [12]. 
Post-LASIK corneal ectasia is a rare, but serious complication of LASIK. The 
condition is similar to keratoconus where the cornea starts to bulge forwards 
at a variable time after LASIK. The disease is mainly manifested by progres-
sive corneal steepening, an increase in myopia (short-sightedness), corneal ab-
errations, plus astigmatism and the loss of visual acuity [3]. 
 
A0003 – What are the known risk factors for keratoconus  
or post-LASIK corneal ectasia? 
The pathophysiology of keratoconus is not well known. Genetic factors appear 
to be multifactorial and are considered fundamental to the aetiology and pro-
gression of keratoconus. However, the underlying molecular and/or genetic 
abnormalities are unknown [9, 12]. 
Keratoconus has been linked with systemic conditions such as atopic disease, 
genetic conditions such as trisomy 21 and Turner’s syndrome, and various 
connective tissue disorders, as well as with eye rubbing, rigid contact lens 
wear and ocular trauma [12]. 
In addition, keratoconic corneas also have an accumulation of cytotoxic by-
products, abnormal antioxidant enzymes and increased levels of mitochon-
drial DNA damage. This suggests that ongoing oxidative stress contributes 
to keratoconus [12]. 
Risk factors of post-LASIK corneal ectasia can be abnormal preoperative topo-
graphy, low residual stromal bed (RSB) thickness, young age, low preopera-
tive corneal thickness and/or high myopia [3, 13]. 
 
A0004 – What is the natural course of keratoconus  
or post-LASIK corneal ectasia? 
Keratoconus often occurs during teenage years and classically progresses until 
the 30th or 40th year of life. Many affected individuals experience an arrest of 
the disease’s progression or probably a reduction in the rate of progression [12]. 
Keratoconus has four stages, based on Amsler-Krumeich’s classification sys-
tem (see table below). 
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Table 3.2-1: Amsler-Krumeich’s classification system 
Grade Characteristics 
1 Eccentric corneal steepening 
Induced myopia and/or astigmatism <5 D (dioptre) 
Mean central K readings ≤48 D 
Vogt’s striae, no scars 
2 Induced myopia and/or astigmatism >5 D ≤8 D 
Mean central K readings ≤53 D 
Absence of scarring 
Corneal thickness ≥400 µm 
3 Induced myopia and/or astigmatism >8 D <10 D 
Mean central K readings >53 D 
Absence of scarring 
Corneal thickness 200 to 400 µm 
4 Refraction not measurable 
Mean central K readings >55 D 
Central corneal scarring perforation 
Corneal thickness ≤200 µm 
References: [8, 9] 
 
Corneal ectasia is one of the most devastating complications after LASIK. 
The disease is defined in patients who developed increasing myopia, with or 
without increasing astigmatism, loss of uncorrected visual acuity, often loss 
of best-corrected visual acuity, with keratometric steepening, with or without 
central and paracentral corneal thinning, and topographic evidence of asym-
metric inferior corneal steepening after LASIK procedure. Ectatic changes 
can occur as early as one week or can be delayed up to several years after 
LASIK [3, 13]. 
 
Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of keratoconus or post-LASIK  
corneal ectasia? 
Due to the thinning of the cornea, keratoconus can lead to irregular astigma-
tism and decrease in visual acuity [12]. Furthermore, keratoconus is unique 
among chronic eye diseases as it has an early age of onset (median age of 25 
years) [9]. 
In addition, LASIK permanently thins and weakens the cornea, which may 
lead to progressive steepening or bulging (ectasia) of the cornea with associ-
ated deterioration of vision [6, 13]. 
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A0006 – What are the consequences of keratoconus or post-LASIK 
corneal ectasia for society? 
Keratoconus is associated with a low incidence of 2 per 100,000 people per year 
and a prevalence of approx. 1 per 2,000 people (or 5 per 10,000) [4, 9, 14]. 
Thus, keratoconus is defined as a rare disease13.  
The actual incidence of post-LASIK corneal ectasia is unknown, although the 
reported incidence rate is less than 1% of patients who underwent LASIK [13]. 
Due to low prevalence rates of both indications, the estimated consequences 
for society do not seem considerable, but are so for the affected patients [9, 15].  
 
Current clinical management of the disease or health condition 
A0024 – How is keratoconus or post-LASIK corneal ectasia currently 
diagnosed according to published guidelines14 and in practice? 
In early stages of keratoconus and post-LASIK corneal ectasia, computerised cor-
neal topography (CCT) techniques using curvature-based analysis and newer 
forms of elevation-based tomography appear to be the most sensitive meth-
ods for detecting early keratoconus [9, 13]. Furthermore, a variety of diag-
nostic algorithms can help diagnose early keratoconus and corneal ectasia. 
However, there seems to be no universally diagnostic criterion to diagnose 
early forms of the disease [13].  
In patients with intermediately progressed keratoconus or post-LASIK corne-
al ectasia, computerised corneal topography and elevation-based tomography 
are probably the most widely used diagnosing methods [13]. 
In more advanced cases, the diseases can be diagnosed by characteristic slit-
lamp findings [9, 13]. 
 
A0025 – How is keratoconus or post-LASIK corneal ectasia currently 
managed according to published guidelines14 and in practice? 
Treatment options for post-LASIK corneal ectasia are the same as for kerato-
conus. Therefore, only the treatments for keratoconus are explained – repre-
sentative for both indications. 
There are no drugs known to reverse or prevent keratoconus. However, pa-
tients may slow the disease progression by refraining from rubbing their eyes 
[12, 13].  
Early in the process of keratoconus, the visual impairment is usually correct-
able with soft contact lenses or spectacles. As the disease progresses, it is more 
difficult to refract the patient to a clear visual acuity with soft contact lenses 
or spectacles [12]. 
At the intermediate stage, patients usually experience vision loss that is no 
longer correctable with soft contact lenses or spectacles. The increasing ir-
regularity of the astigmatism may call for rigid, gas-permeable contacts in 
order to achieve clear vision. Some patients require a scleral lens or a piggy-
back configuration consisting of hard contact lenses worn over soft lenses to 
achieve adequate fit, comfort and vision [4, 5, 12].  
                                                             
13 See: http://www.orpha.net/.../...Disease_Search_Simple 
14 No Austrian or German guidelines were identified. 
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For patients who progress to more advanced stages (stage 2 and more) of the 
disease, contact lens wear may become increasingly difficult and often un-
comfortable due to the steepness of the cornea and difficulty in fitting the 
lenses. Contact lens intolerance is a common indication for corneal trans-
plantation at this stage [4, 12]: 
Penetrating keratoplasty (PK) – a corneal transplantation – is the mainstay of 
treatment for keratoconus. The procedure applies to be effective with a low 
rejection rate. In spite of successful surgery, residual corneal astigmatism and 
refractive error usually require additional correction with a contact lens. In 
addition, complications after PK can include allograft rejection, a fixed, di-
lated pupil and, on occasion, recurrence of keratoconus [4, 8]. For patients 
who have moderate keratoconus without significant scarring, there is renewed 
interest in deep anterior lamellar keratoplasty (DALK), especially with the pre-
cision, predictability and convenience of the femtosecond laser for these cas-
es. The DALK technique aims to remove nearly all corneal stroma [4, 5]. 
Furthermore, intrastromal corneal rings or ring segments are also an option, 
particularly if the patient demonstrates disease progression with apical dis-
placement. However, several products are not indicated anymore for kerato-
conus with a certain keratometry (e.g. >70 D for Keraring) [4, 14].  
Besides, collagen cross-linking (CXL) is a relatively new treatment option. CXL 
involves a one-time application of riboflavin solution to the eye that is acti-
vated by illumination with UV light. The riboflavin causes new bonds to form 
across adjacent collagen strands in the stromal layer of the cornea, which re-
covers and preserves some of the cornea's mechanical strength, possibly slow-
ing the progression of the disease [4, 5]. 
 
Target population 
A0007 – What is the target population in this assessment? 
The target population are patients with keratoconus (mainly stages 1-3) or 
post-LASIK corneal ectasia that are contact lens intolerant (patients with ker-
atoconus), have an adequate corneal thickness, particularly around the area 
of the implant incision site, and are without central corneal scarring [7, 9].  
 
A0023 – How many people belong to the target population? 
This question has been defined as not relevant for this report. 
 
A0011 – How much are intrastromal corneal implants utilised? 
Based on the information given in the VAEV, the estimated annual utilisation 
of the intrastromal corneal rings technology in Austria is around 200. 
In 2013, a total of 110,210 inpatient surgical interventions were performed in 
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4 Clinical effectiveness 
4.1 Methods 
Research questions 
Element ID Research question 
Importance 
2 = critical 
1 = optional 
D0001 What is the expected beneficial effect of intrastromal corneal implants 
on mortality? 
1 
D0003 What is the effect of intrastromal corneal implants on the mortality 
due to causes other than keratoconus or post-LASIK corneal ectasia? 
1 
D0005 How do intrastromal corneal implants affect symptoms and findings 
(severity, frequency) of keratoconus or post-LASIK corneal ectasia? 
2 
D0006 How do intrastromal corneal implants affect progression  
(or recurrence) of keratoconus or post-LASIK corneal ectasia? 
2 
D0011 What is the effect of intrastromal corneal implants on patients’ body 
functions? 
1 
D0016 How does the use of intrastromal corneal implants affect activities of 
daily living? 
2 
D0012 What is the effect of intrastromal corneal implants on generic  
health-related quality of life? 
2 
D0013 What is the effect of intrastromal corneal implants on disease-specific 
quality of life? 
2 
D0017 Was the use of intrastromal corneal implants worthwhile 2 
 
The following crucial outcomes were used as evidence to derive a  
recommendation: 
 Length of hospital stay (or time to resume work/normal activities) 
 Re-operation rate 
 Change of visual acuity (change of two or more Snellen lines) 
The implantation of intrastromal corneal implants is supposed to be less in-
vasive than corneal transplantation (see Chapter 2.2). Therefore, the length 
of hospital stay, 3(or time to resume work or normal activities) after the in-
tervention, was chosen as a crucial outcome.  
The re-operation rate (including explantations) is the rate of how frequently 
patients had to be operated again, e.g., due to complications. This outcome 
is an indicator of the “life-expectancy” of the implants and transplants. 
The change of visual acuity can be measured, for example, by uncorrected 
visual acuity (UCVA) or best-corrected visual acuity (BCVA) on the Snellen 
chart. An improvement or worsening of two and more Snellen lines can be 
considered as clinically relevant. Furthermore, the percentage of patients or 
eyes with improved (or worsened) visual acuity (two or more Snellen lines) has 
been defined as more relevant than the mean increase in visual acuity [17, 
18]. Therefore, only those studies where it was possible to cull this informa-
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Besides the three crucial outcomes, two additional outcomes were used to an-
swer efficacy-related outcomes in Chapter 4.2: quality of life and patient satis-
faction. These two outcomes are also presented in Table A1-1 in the Appendix. 
 
Sources 
The assessment of the research questions regarding efficacy-related outcomes 
was based on a systematic literature search from the following sources: 
 Medline via Ovid, 
 Embase, 
 the Cochrane Library, 
 CRD (DARE, NHS-EED, HTA).  
Details of the search strategy can be found in the Appendix (Chapter “Search 
strategies”). Additionally, literature provided by the manufacturers was also 
checked for eligible studies that were not found within the systematic litera-
ture search. 
One author extracted the data (SF) of the included studies and a second au-
thor controlled the extracted data (IZ). If the same data were duplicated in 
multiple articles, only results from the most comprehensive or most recent ar-
ticle were included. Consensus on the inclusion and exclusion of individual 
studies was found in all cases. 
The extracted results of the identified studies are classified by indication (ker-
atoconus and post-LASIK corneal ectasia) and by the individual products 
(Ferrara RingTM, Intacs®, etc.). The studies in the extraction table (Appendix 
Table A1-1) are sorted by publication date, starting with the oldest study. 
 
Analysis 
The relevant information from the feasible studies was retrieved without any 
further analysis. For all studies the methodological quality was assessed us-
ing the a checklist for case series [19] by two review authors (SF, IZ), inde-
pendently from each other. The risk of bias analysis for each individual study 
is shown in the Appendix (Chapter “Risk of bias tables”). 
 
Synthesis 
Most of the research questions will be answered in plain text format. In ad-
dition, evidence tables are used to show relevant information on the individ-
ual studies. Based on the evidence tables, data on each selected outcome cat-
egory were synthesised across studies according to GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) [20]. 
The analysis is qualitative and not quantitative due to a lack of comparison 
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4.2 Results 
Included studies 
For evaluating efficacy-related outcomes we accepted RCTs, prospective non-
randomised controlled trials and – in case we were unable to identify relevant 
controlled studies – single-arm studies (see Chapter 1.2). 
We could not identify any controlled trials comparing intrastromal corneal 
implants with either corneal transplantation or no intervention for the treat-
ment of keratoconus or post-LASIK corneal ectasia. Therefore, we included 
uncontrolled studies (single-arm studies). 
The only studies that met our inclusion criteria are five single-arm studies 
with a total of 627 eyes [21-25] assessing the efficacy of intrastromal corneal 
implants for the treatment of keratoconus. 
The mean age of patients differed between 26 and 37 years [23, 25]. The mi-
nority of patients were females (30-50%) [22-25] with grade I to IV of kera-
toconus [21, 23, 24]. The follow-up of the studies was 12 months [21-23], 24 
months and up to 96 months (8 years). The loss to follow-up rate differed be-
tween 18 and 76% [21-25]. 
Intacs® were implanted in all studies [21-25]. Furthermore, Keraring intra-
corneal ring segments were implanted in two studies [23, 25]. 
There were no studies assessing the clinical effectiveness of other products, 
like Ferrara RingTM, MyoRing® or probably Bisantis Segment (see Chapter 
2.2) for the treatment of keratoconus. In addition, there were no studies as-
sessing the clinical effectiveness of intrastromal corneal implants for the treat-
ment of post-LASIK corneal ectasia. 
The detailed study characteristics and results of the included studies are dis-
played in Table A1-1 in Appendix Capter “Evidence tables of individual stud-
ies included for clinical effectiveness and safety”. 
Length of hospital stay (or time to resume work/normal activities) and re-
operation rate were not considered for recommendation: Only a direct com-
parison with corneal transplantation would have been allowed to assess the 
clinical effectiveness of intrastromal corneal implants for a treatment of ker-
atoconus and post-LASIK corneal ectasia. 
 
Mortality  
D0001 – What is the expected beneficial effect of intrastromal  
corneal implants on mortality? 
D0003 – What is the effect of intrastromal corneal implants on the 
mortality due to causes other than keratoconus or post-LASIK corneal 
ectasia? 
Mortality is not a relevant outcome for assessing the clinical effectiveness of 
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Morbidity 
D0005 – How do intrastromal corneal implants affect symptoms and 
findings (severity, frequency) of keratoconus or post-LASIK corneal ectasia? 
Answering this research question was based on the outcome “change of visual 
acuity”. Due to a lack of controlled trials, the effect on visual acuity of intra-
stromal corneal implants for a treatment of keratoconus cannot be compared 
with corneal transplantation, but will be based on uncontrolled data. 
The change of visual acuity of one and more Snellen lines was reported in four 
single-arm studies. After 12 months, UCVA was improved in around 70-80% 
of eyes and worsened in less than 10% of eyes after 12 months [23, 24]. After 
24 months, UCVA improved in 81% and worsened in 5% of treated eyes [24]. 
Similarly, BCVA improved in approx. 60-85% and worsened in 4-12% of the 
treated eyes (after 24 months: 68% improved, 15% worsened) [23, 24]. More-
over, the improvement of UCVA and BCVA was considered statistically sig-
nificant after six 6 and 12 months of implantation in one study [24]. 
The change of visual acuity of two or more Snellen lines after treatment, which 
has been defined as clinically relevant, has been reported in one single-arm 
study for UCVA [21] and in two single-arm studies for BCVA [21, 22]: 
Six months after implantation, UCVA improved in 79% and worsened in 
none of the treated eyes [21]. In addition, BCVA rather improved in more 
eyes than worsened [21, 22]: For example, after 6 months of implantation 
BCVA improved in 39-62% and worsened in 6-12% of eyes [21, 22]. After 12 
months of implantation, BCVA improved in 42% and worsened in 8% of the 
eyes that received an implant [22]. The improvement of UCVA and BCVA 
after six months of implantation compared to baseline was considered as sta-
tistically significant in one study [21]. 
 
D0006 – How do intrastromal corneal implants affect progression  
(or recurrence) of keratoconus or post-LASIK corneal ectasia? 
To answer this research question the outcome “re-operation rate” was used 
to (indirectly) measure the progression (or recurrence) of the disease. Thus, 
the higher the re-operation rate, the lower the chance of stopping or slowing 
the progression. 
However, due to a lack of controlled trials, the effect on the re-operation rate 
of intrastromal corneal implants for a treatment of keratoconus cannot be com-
pared with corneal transplantation, but will be based on uncontrolled data 
According to the available data, between 4 and 23% of the eyes with an im-
planted intrastromal corneal ring had to be re-operated [21, 22, 24, 25]. 
 
Function 
D0011 – What is the effect of intrastromal corneal implants  
on patients’ body functions? 
Keratoconus and the treatment with intrastromal corneal implants exclu-
sively affect the eyes and not the whole body. Thus, answering this research 
questions has been defined as not relevant. 
The effect on visual acuity (the only affected body function) has already been 
addressed in the previous section (question D0005). 
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D0016 – How does the use of intrastromal corneal implants  
affect activities of daily living? 
Answering this research question was based on the outcome “length of hos-
pital stay (or time to resume work/normal activities)”. The outcome was not 
reported in any of the identified single-arm studies. 
 
Health-related quality of life 
D0012 – What is the effect of intrastromal corneal implants  
on generic health-related quality of life? 
No evidence was found to answer this research question (no identified study 
reported generic health-related quality of life). 
 
D0013 – What is the effect of intrastromal corneal implants  
on disease-specific quality of life? 
To answer this research question the outcome “vision-related quality of life” 
was used. Due to a lack of controlled trials, the effect on quality of health of 
intrastromal corneal implants for a treatment of keratoconus cannot be com-
pared with corneal transplantation, but will be based on uncontrolled data. 
Vision-related quality of life was reported in two single-arm studies [21, 22]. 
In one study, vision-related quality of life improved in 88.5% and worsened 
in 11.5% of patients, measured with the Visual Function-7 score (no informa-
tion on this questionnaire was presented) [22]. In another study, the quality 
of vision was measured with the characteristics “poor”, “fair”, “good” and 
“excellent” by asking the patients [21]. Before implantation, 70% of patients 
had a “poor”, and none had an “excellent” quality of vision. At 6 months af-
ter implantation, 24% of patients had “poor” and 9% of patients had “excel-
lent” quality of vision [21]. 
 
Patient satisfaction 
D0017 – Was the use of intrastromal corneal implants worthwhile? 
To answer this research question the outcome “patient satisfaction” was used. 
Due to a lack of controlled trials, the effect on patient satisfaction of intra-
stromal corneal implants for a treatment of keratoconus cannot be compared 
with corneal transplantation, but will be based on uncontrolled data. 
The outcome was reported in one of the identified single-arm studies as the 
change of self-reported satisfaction with vision [22]. According to that study, 
73% of patients reported an improvement in satisfaction and 8% reported a 






















Element ID Research question 
Importance 
2 = critical 
1 = optional 
C0008 How safe are intrastromal corneal implants in comparison to corneal 
transplantation or no intervention? 
2 
C0002 Are the harms related to dosage or frequency of applying intrastromal 
corneal implants? 
1 
C0004 How does the frequency or severity of harms change over time or in 
different settings? 
2 
C0005 What are the susceptible patient groups that are more likely to be 
harmed through the use of the intrastromal corneal implants? 
2 
C0007 Are intrastromal corneal implants and corneal transplantation (or no 
intervention) associated with user-dependent harms? 
2 
B0010 What kind of data/records and/or registry are needed to monitor the 
use of intrastromal corneal implants and corneal transplantation  
(or no intervention)? 
2 
 
The following crucial outcomes were used as evidence to derive a  
recommendation: 
 intra-operative adverse events 
 post-operative adverse events. 
Intra-operative adverse events are those complications that occur during the 
surgical procedure: during the ring implantation or during the corneal trans-
plantation. Post-operative adverse events are those complications that occur 




The assessment of the research questions regarding safety-related outcomes 
was based on a systematic literature search from the following sources: 
 Medline via Ovid, 
 Embase, 
 the Cochrane Library, 
 CRD (DARE, NHS-EED, HTA). 
Details of the search strategy can be found in the Appendix (Chapter “Search 
strategies”). Additionally, literature provided by the manufacturers was also 
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One author extracted the data (SF) of the included studies and a second au-
thor controlled the extracted data (IZ). If the same data were duplicated in 
multiple articles, only results from the most comprehensive or most recent ar-
ticle were included. Consensus was found in all cases about the inclusion 
and exclusion of individual studies. 
The extracted results of the identified studies are classified by indication (ker-
atoconus and post-LASIK corneal ectasia) and by the individual products 
(Ferrara Ring™, Intacs®, etc.). The studies in the extraction tables are sorted 
by publication date, starting with the oldest study. 
 
Analysis 
The relevant information from the feasible studies was retrieved without any 
further analysis. For all studies the methodological quality was assessed using 
a checklist for case series [19], by two review authors (SF, IZ), independently 
from each other. The risk of bias analysis for each individual study is shown 
in the Appendix (Chapter “Risk of bias tables”). 
Incidentally, a comparative analysis was not applicable, since we could not 
identify studies for every product and indication. Moreover, the quality of 
evidence did not allow any comparative analysis. 
 
Synthesis 
Most of the research questions will be answered in plain text format. In ad-
dition, evidence tables are used to show relevant information on the individ-
ual studies. Based on the evidence tables, data on each selected outcome cat-
egory were synthesised across studies according to GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) [20]. 
The analysis is qualitative and not quantitative due to a lack of comparison 





For evaluating safety-related outcomes we accepted RCTs, prospective non-
randomised controlled trials and – in case we were unable to identify relevant 
controlled studies – single-arm studies (see Chapter “Risk of bias tables”).  
However, we could not identify any controlled trials comparing intrastromal 
corneal implants with either corneal transplantation or no intervention for 
the treatment of keratoconus or post-LASIK ectasia.  
The only studies that met our inclusion criteria are five single-arm studies 
with a total of 627 eyes [21-25] assessing the safety of intrastromal corneal 
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The mean age of patients differed between 26 and 37 years [23, 25]. The mi-
nority of patients were females (30-50%) [22-25] with grades I to IV of kera-
toconus [21, 23, 24]. The follow-up of the studies was 12 months [21-23], 24 
months up to 96 months (8 years). The loss to follow-up rate differed between 
18 and 76% [21-25]. 
Intacs® were implanted in all studies [21-25]. Furthermore, Keraring intra-
corneal ring segments were implanted in two studies [23, 25]. 
The detailed study characteristics and results of the included studies are dis-
played in Table A1-1 in Appendix Evidence tables of individual studies in-
cluded for clinical effectiveness and safety. 
There were no studies assessing the safety of other products, like Ferrara 
Ring™, MyoRing® or probably Bisantis Segment (see Chapter 2.2) for the treat-
ment of keratoconus. In addition, there were no studies assessing the safety 




C0008 – How safe are intrastromal corneal implants in comparison  
to corneal transplantation or no intervention? 
No studies were identified that are directly comparing the implantation of in-
trastromal corneal implants with corneal transplantation (e.g., keratoplasty) 
or no intervention for the treatment of keratoconus. 
In the single-arm studies, general adverse events occurred in 7 to 16% of the 
eyes [21-24]. Intra-operative adverse events, like difficulties in forming the 
intrastromal tunnel to implant the rings or anterior perforation, occurred in 
0-2% of the eyes [21-24]. Post-operative adverse events occurred in 2 to 23% 
of the treated eyes [21-25], e.g., extrusion or migration of a segment, external 
infection or corneal perforation. 
 
C0002 – Are the harms related to dosage or frequency  
of applying intrastromal corneal implants? 
Naturally, since the implantation of intracorneal rings is performed only once, 
the question is not relevant.  
 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No direct evidence was found to answer this research question in an appro-
priate way. 
However, it seems likely that the frequency and/or severity of harms slightly 
increase over time. The identified study with the longest duration and the 
most patients is the only one that shows the number of post-operative events 
per year of follow-up [25]. In Figure 5.2-1, the number and the percentage of 
post-operative events (per number of patients in the study) per year are shown. 
PatientInnen:  
Ø 26-37 Jahre, 30-50 % 
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Nachbetrachtungszeit 
12-96 Monate 
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Figure 5.2-1: Number and percentage of post-operative events 
 
C0005 – What are the susceptible patient groups that are more likely to 
be harmed through the use of the intrastromal corneal implants? 
No direct evidence was found to answer this research question.  
 
C0007 – Are intrastromal corneal implants and corneal transplantation 
(or no intervention) associated with user-dependent harms? 
No direct evidence was found to answer this research question. However, in 
all included studies intrastromal corneal implants were implanted by expe-
rienced eye surgeons [21-25].  
 
Investments and tools required 
B0010 – What kind of data/records and/or registry are needed to monitor 
the use of intrastromal corneal implants and corneal transplantation  
(or no intervention)? 
No literature was retrieved that identified specific data or monitoring records 
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6 Quality of evidence 
The strength of evidence was rated according to the GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) approach [20] for 
every defined outcome parameter individually. Each study was rated by two 
independent researchers (SF, IZ). All relevant study results for each endpoint 
were thereby summarised and assessed regarding the strength of evidence. 
In case of disagreement, a third researcher was involved to solve the differ-
ence. A detailed description of the used criteria for assessing the strength of 
evidence is stated in the internal manual of the LBI-HTA [26] or in the rec-
ommendations of GRADE, respectively [20]. The ranking according to the 
GRADE scheme for the research question can be found in Table 6–1.  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that of 
the estimate of the effect15;  
 Moderate = We are moderately confident in the effect estimate:  
the true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect16;  
 Very low: Evidence either is unavailable or does not permit a  
conclusion. 
Overall, the strength of evidence for clinical effectiveness and the safety of 
intrastromal corneal implants for the treatment of keratoconus is low to very 
low.  
There was neither any evidence available to assess the efficacy, nor to assess 
the safety of intrastromal corneal implants for the treatment of post-LASIK 
corneal ectasia (compared to corneal transplantation or no intervention) that 
matched our inclusion criteria. 
 
 
                                                             
15 In case of RCTs: the strength of evidence starts with “high”. 
16 In case of observational studies (e.g., single-arm studies): the strength of evidence 
starts with “low”. 
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Table 6–1: Evidence profile: Efficacy and safety of intrastromal corneal implants for keratoconus (single-arm studies) 
No of studies/ 






Change of visual acuity: UCVA (in % of improved/worsened eyes ≥2 Snellen lines) 
1/59 Single-arm study 6 mo: 79/0; p=S.S. from baseline  No serious limitations n/a (only 1 trial) Direct None Low 











1 mo: 26/8 
3 mo: 41/8 
6 mo: 39-62/6-12; p=S.S. from 
baseline, in one study 
12 mo: 42/8 
No serious limitations 
No serious limitations 
No serious limitations 
 
No serious limitations 
n/a (only 1 trial) 
n/a (only 1 trial) 
Important inconsistency17 (-1) 
 

















Adverse events: intraoperative (in % of eyes) 
4/377 Single-arm studies 0-2 No serious limitations No important inconsistency Direct None Low 
Adverse events: post-operative (in % of eyes) 
5/627 Single-arm studies 2-23 No serious limitations Important inconsistency18 (-1) Direct None Very low 
Abbreviations: BCVA = best-corrected visual acuity; UCVA = uncorrected visual acuity; S.S. = statistically significant 
 
 
                                                             
17 The difference between the lowest and the highest percentage of eyes with improved BCVA was more than 20%. 
18 The difference between the lowest and the highest rate of postoperative events was more than 20%. 
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7 Discussion 
Keratoconus and post-LASIK corneal ectasia are rare diseases, affecting 1 per 
2,000 people in case of keratoconus and probably less in case of post-LASIK 
ectasia. Even if both diseases are not common and the impact for society is 
minor, the diseases severely reduce the quality of life of the persons affected, 
due to low visual acuity. Furthermore, the diagnosis of the diseases can result 
in occupational disability in several professions (e.g., police, military and avia-
tion). 
The aim of this report was to assess the clinical effectiveness and safety of a 
treatment of keratoconus or post-LASIK ectasia with intrastromal corneal rings 
(or ring segments) compared to corneal transplantations (or no intervention). 
Overall, there were no controlled trials available to assess the clinical effec-
tiveness or safety of intrastromal corneal implants in comparison to corneal 
transplantations (or no intervention). In total, we selected 5 single-arm stud-
ies with 627 eyes that met our inclusion criteria [21-25]. Two of these studies 
[21, 22] were considered for recommendation based on efficacy-related out-
comes.  
All identified studies included patients with keratoconus, with one exception 
where a few patients had myopia or post-LASIK corneal ectasia [25]. How-
ever, since keratoconus and post-LASIK corneal ectasia are very similar, the 
studies for keratoconus are more or less transferable. All studies implanted 
either Intacs® or Keraring. 
All studies (when stated) included young (mean age: 26-37) [23, 25] and pre-
dominantly male patients (50-70%) [22-25]. The stage of keratoconus was 
grades I-IV [21, 23, 24] and patients had (mostly) contact lens intolerance. 
All these factors seem to reflect the “ordinary” population of keratoconus that 
is feasible for implantation of intrastromal corneal implants. 
Overall, the strength of evidence for efficacy and safety is low to very low. 
Naturally, this is mainly due to the study design of the identified single-arm 
studies: the strength of evidence of observational studies generally starts with 
“low”. In addition, for change of visual acuity (BCVA) after 6 months and 
post-operative adverse events, the quality of evidence was downgraded to very 
low due to an important inconsistency (the differences between the lowest and 
highest rates were enormous). 
The majority of studies had a relatively short follow-up of one year [21-23] 
or two years [24] and a high rate of drop outs during the follow-up phase of 
18 to 76%. Only one study had a longer follow-up (or better: study duration) 
of 8 years [25]. Therefore, reliable data of long-term efficacy and safety-related 
outcomes are missing. 
Moreover, several studies had a lack of reporting information of the included 
study population. For example, two studies did not report the number of pa-
tients (only eyes) [21, 25], the age of patients [21, 24] and the clinical classi-
fication of keratoconus [22, 25]; one study did not mention the sex ratio of 
patients [21].  
One outcome that was defined as crucial – the length of hospital stay (or time 
to resume work or normal activities) – was not reported in any of the identi-
fied single-arm studies. Anyway, due to the lack of controlled trials, this out-
come was not considered for recommendation. 
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Four studies reported the change of visual acuity [21-24]. However, only two 
studies [21, 22] allowed culling information on improvement or worsening of 
two or more Snellen lines, which can be considered as clinically relevant. 
Furthermore, in one paper only the reasons for explantations were studied 
[25]. Thus, the real number of post-operative complications is unknown in 
this study, since there were probably complications that did not implicate 
any explantation. 
In another study, it seems very likely that not all post-operative complica-
tions were reported: “Ocular observations at all postoperative examinations 
were minor and were not considered clinically significant by the investiga-
tors” [21]. 
Besides, two studies declared that no author had a financial interest in the 
used products [21, 24]. However, the first author of these studies is a con-
sultant of the investigated product, as well as the editor of the journal the ar-
ticles were published in.  
Considering the findings of the included single-arm studies regarding clini-
cal effectiveness, it seems that the implantation of intrastromal corneal im-
plants can improve visual acuity in a clinically relevant manner (two or more 
Snellen lines). The uncorrected visual acuity improved two or more Snellen 
lines in approx. 80% of the eyes and the best-corrected visual acuity im-
proved two or more Snellen lines in approx. 40-60% of the eyes during 6 to 
12 months of follow-up [21, 22]. 
However, there were also several cases with worsened visual acuity after a 
treatment with intrastromal corneal implants: worsened best-corrected visu-
al acuity (two and more Snellen lines) in 6-12% of the eyes during follow-up 
[21, 22]. 
Only 4-23% of the patients had to be operated again [21, 22, 24, 25]. Further-
more, the re-operations were performed without any injuries. A restriction is 
the relatively short follow-up of the studies.  
Nevertheless, due to a lack of controlled trials we are not able to draw any 
conclusions on the clinical effectiveness of intrastromal corneal implants for 
a treatment of keratoconus or post-LASIK ectasia compared to corneal trans-
plantation or even no intervention. 
In particular, the direct comparison of the length of the hospital stay or the 
time the patients return to their normal activities or work after a treatment 
with intrastromal rings or corneal transplantation is missing. 
Although the strength of evidence for safety was low to very low, a treatment 
of keratoconus (and post-LASIK ectasia) with intrastromal corneal implants 
does not seem to be related with major adverse events. The rate of intra-op-
erative adverse events seems to be low. However, the rate of post-operative 
adverse events was high in several studies. 
Finally, a treatment of keratoconus as well as post-LASIK corneal ectasia with 
intrastromal corneal implants seems relatively safe – at least within a short 
time horizon. Additionally, all explantations or adjustments of intrastromal 
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Naturally, our systematic review has several weaknesses: 
First of all, we excluded case series with less than 50 eyes. There were prob-
ably studies with less than 50 eyes with a longer follow-up or studies im-
planting other products (e.g., Ferrara RingTM or MyoRing®). 
Furthermore, we excluded retrospective studies – even controlled studies with 
a retrospective control group where patients received a corneal transplanta-
tion – because sources of error due to confounding and bias are more com-
mon in retrospective studies than in prospective ones.  
There were two studies included without precise information on whether they 
were conducted pro- or retrospectively [23, 25].  
One of the studies also included patients who had other diseases than kera-
toconus or post-LASIK corneal ectasia (e.g., myopia) [25]. Hence, we had to 
exclude this study although it included a large number of patients and had a 
long follow-up. 
A major issue is that keratoconus and post-LASIK corneal ectasia are rare 
diseases with a low incidence, resulting in low patient numbers. There are 
even fewer patients who are contact lens intolerant and/or need a corneal 
transplantation (and are therefore eligible for implantation of intrastromal 
corneal rings). Therefore, it is difficult to conduct prospective controlled tri-
als or randomised controlled trials for assessing the clinical effectiveness of 
intrastromal corneal implants compared to corneal transplantation (or no in-
tervention). An additional issue for conducting controlled trials is that one 
study group needs an adequate donor for the corneal transplant and patients 
must wait for the transplantation. 
Thus, the FDA approved one device (Intacs® and supplying products) under 
the Humanitarian Device Exemption (HDE) program, by only assessing the 
safety. That means the product may only be used in facilities that have an 
institutional review board to supervise clinical testing. The device must be for 
humanitarian use and the effectiveness of the device for the specific indica-
tion does not have to be demonstrated. 
Nevertheless, we identified two abstracts of two RCTs that compared intra-
stromal corneal ring segments with keratoplasty for a treatment of kerato-
conus [27, 28], but were not able to find full texts of these RCTs. We directly 
contacted one study author and tried to reach another study author – without 
any reply (status: 18th March 2015). 
Although conducting RCTs of intrastromal corneal implants versus corneal 
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8 Recommendation 
In Table 8–1, the scheme for recommendations is displayed and the according 
choice is highlighted. 
Table 8–1: Evidence-based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
X The inclusion in the catalogue of benefits is recommended with restrictions. 
 The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that intrastromal corneal im-
plants are equally or more effective and safe than corneal transplantation or 
no intervention for a treatment of keratoconus or post-LASIK corneal ectasia. 
However, the comparison before and after the ring implantations of the single-
arm studies have shown that the visual acuity has improved after implanting 
intrastromal corneal rings/ring segments and that improvement has been clin-
ically relevant in a large proportion of patients. 
Furthermore, the implantation of intrastromal corneal rings seems to be rel-
atively safe and adverse events were minor. In cases where the implants had 
to be explanted or readjusted, this was performed without any complications 
or injuries. 
A major benefit of intrastromal corneal implants compared to corneal trans-
plantation is their reversibility (the rings can be explanted relatively easily); 
the rings can be ordered when they are required (for corneal transplantation 
an adequate donor is needed) and after implantation no immunosuppressive 
drugs are needed. Moreover, corneal transplantation is a more invasive inter-
vention with higher risks for complications than the implantation of intra-
stromal corneal rings. Due to the minor invasivity and the reversibility, in-
trastromal corneal implants should be considered before corneal transplan-
tation. 
The inclusion in the catalogue of benefits is recommended with the follow-
ing restrictions: 
 The patient has contact lens intolerance (or is not able to wear 
contact lenses anymore). 
 The individual indications and contra-indications for the use of the 
several products must be considered (e.g. adequate thickness of cornea). 
 The implantation of intrastromal corneal rings (or ring segments) 
should exclusively be offered in big centres, like medical universities. 
 The safety of intrastromal corneal implants for a treatment of kerato-
conus or post-LASIK corneal ectasia should be monitored and record-
ed in a national database. The data can be used to further adapt the 
recommendations for the use of intrastromal corneal implants. 
Empfehlungsschema 
kein Beweis, dass Ringe 
wirksamer und sicherer 
als Transplantation 
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Currently, there are no registered ongoing or planned controlled trials com-
paring intrastromal corneal implants with corneal transplantation for a treat-
ment of keratoconus or post-LASIK ectasia (see Appendix Capter “Ongoing 
studies”). Additionally, two ongoing RCTs are comparing different intra-
stromal corneal implants for a treatment of keratoconus. 
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Evidence tables of individual studies included for clinical effectiveness and safety 
Table A1-1: Results from single-arm studies of intrastromal corneal implants for keratoconus 
Author, year,  
reference number Hellstedt 2005 [22] Colin 2006 [21] Colin 2007 [24] Ferrer 2010[25] Kubaloglu2010 [23] 
Country Finland France, Germany, UK France Spain Turkey 
Study design Single-arm study,  
prospective 
Single-arm study,  
prospective 






Sponsor Supported by Finnish 
government and Finnish Eye 
Foundation 
Unclear21 Unclear21 Spanish Ministry of Health None 
Intervention/Product ICRS (Intacs®), topical 
anaesthetics, manual tunnel 
creation 
ICRS (Intacs®), topical or 
general anaesthetics, manual 
tunnel creation 
ICRS (Intacs®), topical or 
general anaesthetics, manual 
tunnel creation 
ICRS (Intacs® and Keraring), 
used anaesthetics not stated, 
manual or femtosecond laser 
tunnel creation 
ICRS (Intacs® and Keraring), 
topical anaesthetics, manual 
or femtosecond laser tunnel 
creation 
Comparator None None None None None 
Number of eyes/pts. 50/37 59/n/a 100/82 250/n/a22 Total: 168/119 
Keraring: 100/77 
Intacs®: 68/42 
Age of patients (yrs.)  20-6923 n/a n/a Ø 37 (17-64) Total: Ø 26 (18-57) 
Keraring: Ø 26 (18-57) 
Intacs®: Ø 26 (18-45) 
Sex (% female) 30 n/a 35 49 Total: 48 
Keraring: 47 
Intacs®: 50 
                                                             
19 It is not stated whether the study was conducted pro- or retrospectively. Contacting the authors did not bring a result. However, the study seems to be prospective. 
20 The study was conducted as a controlled trial comparing two products of intrastromal corneal ring implants (Intacs® and Keraring). However, for the purposes of this review each 
study group was analysed separately and therefore the study was considered a single-arm study. 
21 Authors declare no financial interest. However, the first author is a consultant of the manufacturer. 
22 The study evaluated ICRS that were explanted in several centres in Spain during 2000 and 2008. A total of 250 implantations were performed during this period. The rates regarding 
age and sex refer to the patients with ICRS explantations. 
























Author, year,  
reference number Hellstedt 2005 [22] Colin 2006 [21] Colin 2007 [24] Ferrer 2010[25] Kubaloglu2010 [23] 
Clinical classification n/a Grade I-II Grade I-III n/a24 Grade I-IV 
Primary endpoint(s) n/a Safety of the device, 
maintenance of BCVA, 
improvement in UCVA, 
reduction in manifest 
refraction spherical 
equivalent, reduction in 
asymmetric astigmatism 
Adverse events, visual acuity 
outcome, determine the 
efficacy of the segments 
n/a n/a 
Inclusion criteria Patients with: keratoconus, 
clear central cornea and 
contact lens intolerance, 
BSCVA of ≥20/100 in the 
treatment eye, corneal 
thickness of ≥400 µm 
n/a Patients had been referred 
for a PKP procedure due to 
contact lens intolerance, with 
Amsler-Krumeich grades I, II, 
and III keratoconus + no 
central corneal opacities or 
scarring 
n/a25 Patients with keratoconus, 
clear central cornea and 
contact lens intolerance 
Follow-up (months) 12 (Ø 6.3)26 1227 24 96 (8 yrs.) 1228 
Loss to follow-up,  
n (%) of eyes 
38 (76) 25 (42)29 18 (18) n/a30 53 (32) 
Efficacy-related outcomes 
Length of hospital 
stay/time to work 
resumption in days 
n/a n/a n/a n/a n/a 
Re-operation rate  
in % (n) eyes 
22 (11)31 12 (7)32 4 (4)33 23 (57)34 n/a 
                                                             
24 The majority of patients had primary keratoconus (80%), post-LASIK ectasia (12%), marginal pellucid degeneration (5%), previous keratoplasty (1.5%) or myopia (1.5%). 
25 Since the study evaluated all patients with an explantation of intrastromal corneal ring segments, no inclusion criteria were needed. 
26 Follow-up was up to 12 months. However, 8 patients (10 eyes) were followed up for more than 12 months. 
27 Most outcomes (especially adverse events) were reported after 6 months. 
28 Follow-up was at least six months for all eyes/patients and up to 12 months for some eyes/patients. 
29 This contains only eyes that were lost to follow-up until the 6th month of follow-up. Reasons for drop-outs not stated. 
30 Actually, study duration (or follow-up) was 8 years to evaluate the reasons of explantations; therefore, a loss to follow-up is not applicable, plus the duration of follow-up does not 
apply for all patients. 
31 Segments/rings were removed in 4 eyes (8%) and adjusted in 7 eyes (14%). 
32 Segments/rings were partially or totally removed in 7 eyes (12%). 
33 Segments/rings were removed in 4 eyes (4%). 















Author, year,  
reference number Hellstedt 2005 [22] Colin 2006 [21] Colin 2007 [24] Ferrer 2010[25] Kubaloglu2010 [23] 
Change of visual 
acuity 
UCVA (improved/ 
worsened % of eyes)35: 
After 1, 3 months: n/a 
After 6 months: 73/7; p=n/a 
After 12, 24 months: n/a 
BCVA (improved/ 
worsened % of eyes)36: 
Baseline: - 
After 1 month: 26/8; p=n/a 
After 3 months: 41/8; p=n/a 
After 6 months: 39/12; p=n/a 
After 12 months: 42/8; p=n/a 
After 24 months: n/a 
UCVA(improved/ 
worsened % of eyes)36: 
Baseline: - 
After 1, 3 months: n/a 
After 6 months: 79/0; 
p<0.001 from baseline 
After 12, 24 months: n/a 
BCVA(improved/ 
worsened % of eyes)36: 
Baseline: - 
After 1, 3 months: n/a 
After 6 months: 62/6; 
p<0.001 from baseline 
After 12, 24 months: n/a 
UCVA (improved/ 
worsened % of eyes)35: 
Baseline: - 
After 1, 3, 6 months: n/a 
After 12 months: 69/9; 
p<0.001 from baseline 
After 24 months: 81/5; 
p<0.001 from baseline 
BCVA(improved/ 
worsened % of eyes)35: 
Baseline: - 
After 1, 3, 6 months: n/a 
After 12 months: 61/12; 
p<0.001 from baseline 
After 24 months: 68/15; 
p<0.001 from baseline 
n/a UCVA (improved/ 
worsened % of eyes)35: 
Baseline: - 
After 1, 3, 6 months: n/a 
After 12 months: 
Keraring: 83/7; p=n/a 
Intacs®: 82/7; p=n/a 
After 24 months: n/a 
BCVA(improved/ 
worsened % of eyes)35: 
Baseline: - 
After 1, 3, 6 months: n/a 
After 12 months: 
Keraring: 85/4; p=n/a 
Intacs®: 82/7; p=n/a 
After 24 months: n/a 
Quality of life  
(health- or  
vision-related) 
Change of Visual Function-7 
score37 (improved/worsened 
% of pts.): 
Baseline: - 
After 1, 3 months: n/a 
After 6 months: 88.5/11.5 
After 12, 24 months: n/a 
Quality of vision 
(poor/fair/good/excellent in 
% of pts.): 
Baseline: 70/20/10/0 
After 1, 3 months: n/a 
After 6 months: 24/29/38/9; 
P<0.001 from baseline 
After 12, 24 months: n/a 
n/a n/a n/a 
Patient satisfaction Change of self-reported 
satisfaction with vision 
(improved/worsened % of 
pts.): 
Baseline: - 
After 1, 3 months: n/a 
After 6 months: 73/8 
After 12, 24 months: n/a 
n/a n/a n/a n/a 
                                                             
35 Improvement/declining were considered as change of 1 Snellen line and more. 
36 Improvement/declining were considered as change of 2 Snellen lines and more. 

























Author, year,  
reference number Hellstedt 2005 [22] Colin 2006 [21] Colin 2007 [24] Ferrer 2010[25] Kubaloglu2010 [23] 
Safety-related outcomes 
Adverse events,  
general in % (n) eyes 
16 (8) 15 (9)38 2 (2) n/a Keraring: 7 (7) 
Intacs®: 10 (7) 
Adverse events,  
intra-operative  
in % (n) eyes 
2 (1) 
(difficulty in forming 
intrastromal tunnel) 
0(0) 0 (0) n/a Keraring: 1 (1) 
Intacs®: 0 (0) 
(anterior perforation) 
Adverse events,  
post-operative  
in % (n) eyes 
14 (7) 
(external infection, segment 
migration, surgical aim not 
achieved) 
15 (9) 
(discomfort, glare, itching, 
burning, photophobia, 
difficulty with night vision, 
fluctuating vision) 
2 (2) 
(extrusion of a segment) 
23 (57) 
(extrusion, refractive failure, 
corneal melting, corneal 
perforation) 
Keraring: 6 (6) 
Intacs®: 10 (7) 
(extrusion, decentration, 
shallow placement) 
Abbreviations: BCVA = best-corrected visual acuity; BSCVA = best spectacle-corrected visual acuity; ICRS = intrastromal corneal ring segments; PKP = penetrating keratoplasty; n = number; 
n/a = not applicable; pts. = patients; UCVA = uncorrected visual acuity; yrs. = year 
 
 
Risk of bias tables 
The internal validity of the included studies was judged by two independent researchers. In case of disagreement, a third researcher was involved to solve the dif-
ferences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the 
LBI-HTA and in the Guidelines of EUnetHTA [26].  
Table A2-1: Risk of bias – study level of single-arm studies 
18 criteria checklist:  












Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction, or methods section? Yes Yes Yes Yes Yes 
Study population 
Are the characteristics of the participants included in the study described? Yes No39 No40 No41 Yes 
                                                             
38 Complications were counted in patients and not in eyes. However, the rates were based on the number of eyes.  
39 The number, age and sex of patients were not stated. 
40 The age of patients was not stated. 















18 criteria checklist:  











Were the cases collected in more than one centre? No Yes No Yes No 
Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit and appropriate? Yes No42 Yes n/a43 Yes 
Were participants recruited consecutively? Yes Yes Yes Yes Yes 
Did participants enter the study at similar point in the disease? Yes Unclear Yes No44 Yes 
Intervention and co-intervention 
Was the intervention clearly described in the study? Yes Yes Yes No Yes 
Were additional interventions (co-interventions) clearly reported in the study? Yes Yes Yes No Yes 
Are the outcome measures clearly defined in the introduction or methods section? Yes Yes Yes Yes Yes 
Were relevant outcomes appropriately measured with objective and/or subjective methods? Yes Yes Yes Yes Yes 
Were outcomes measured before and after intervention? Yes Yes Yes n/a45 Yes 
Statistical analysis 
Were the statistical tests used to assess the relevant outcomes appropriate? Yes n/a46 Yes n/a46 Yes 
Results and conclusions 
Was the length of follow-up reported? Yes Yes Yes Yes Yes 
Was the loss to follow-up reported? No47 Yes Yes n/a48 No47 
Does the study provide estimates of the random variability in the data analysis of relevant outcomes?49 n/a n/a n/a n/a n/a 
Are adverse events reported? Yes Yes Yes Yes Yes 
Are the conclusions of the study supported by results? Yes Yes Yes Yes Yes 
Competing interests and sources of support 
Are both competing interests and sources of support for the study reported? Yes No50 No50 Yes Yes 
 
                                                             
42 The inclusion criteria were not stated. 
43 Since the study evaluated all patients with an explantation of intrastromal corneal ring segments, no inclusion criteria were needed. 
44 The majority of patients had keratoconus, whereas several patients had other diseases. 
45 Study investigated only explantations/removals of intrastromal corneal ring segments. 
46 There was no description whether a statistical test was performed or not. 
47 The loss to follow-up was not clearly mentioned. 
48 Study duration was 8 years to evaluate the reasons of explantations, therefore a loss to follow-up is not applicable, plus the duration of follow-up does not apply for all patients. 
49 This criterion was not applicable for the relevant outcomes that were used for recommendation. 

























Table A2-2: Risk of bias – outcome level of single-arm studies (crucial outcomes used for recommendation) 
Outcome 
Trial 
Risk of bias –  
study level 






Other aspects according 
to risk of bias 
Risk of bias –  
outcome level 
Change of visual acuity 
(UCVA/BCVA: improved/worsened % of eyes) 
Hellstedt 2005 Low Not possible High Low Low Low 
Colin 2006 Low Not possible High Low Low Low 
Adverse events 
(intra- and post-operative) 
Hellstedt 2005 Low Not possible High Low Low Low 
Colin 2006 Low Not possible High High51 High52 High 
Colin 2007 Low Not possible High Low High52 High 
Ferrer 2010 Low Not possible High Low Low Low 
Kubaloglu 2010 Low Not possible High Low Low Low 
 
 
                                                             
51 Study says: “ocular observations at all postoperative examinations were minor and were not considered clinically significant by the investigators”. 
52 The first author is the editor of the journal the study was published in. 
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Applicability table 
Table A3-1: Summary table characterising the applicability of a body of studies (single-arm studies) 
Domain Description of applicability of evidence 
Population None of the studies distinguished between male and female or young or elderly patients when 
recruiting patients for the study. The majority of patients had keratoconus, with grades I-IV 
(stated in three studies). One study included also (a few) patients with other diseases than 
keratoconus (e.g., myopia). There was no study that exclusively included patients with  
post-LASIK corneal ectasia. 
The inclusion criteria and the population in the studies seem to be in accordance with the 
intended patient population for the technology. 
Intervention The implantation of intrastromal corneal implants was performed using commercially available 
devices. Patients in the included studies received either Intacs® or Keraring. 
The devices were either inserted under general or topical anaesthetics. In the majority of 
studies the tunnel creation for inserting the implants was performed manually or by using a 
femtosecond laser. 
Comparators To date, there are no published studies in which intrastromal corneal implants have been 
compared with corneal transplantation or no intervention. 
Outcomes A range of clinically relevant outcome criteria were applied in the studies and have shown 
objective and/or subjective benefits from intrastromal corneal implants for the treatment of 
keratoconus. However, due to limited data, especially lack of comparative data, it is not possible 
to evaluate the clinical effectiveness of intrastromal corneal implants for the treatment of 
keratoconus or post-LASIK corneal ectasia. 
For the assessment of safety, intra- and/or post-operative adverse events were recorded.  
Setting With one exception, the studies were carried out in Europe: in Finland, France, Germany and 
Spain. One study was carried out in Turkey. Patients were recruited from and the operations 
were performed at ophthalmologic centres in- or outpatiently. Study centres had experience  
in the technology used, as well as in clinical research in general.  
The settings of the studies reflects the clinical setting in which the technology is intended to 
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Search strategies 
Medline via OVID 
Database: Ovid MEDLINE(R) <1946 to November Week 3 2014>, Ovid MEDLINE(R) In-Process & 
Other Non-Indexed Citations <December 24, 2014>, Ovid MEDLINE(R) Daily Update <November 19, 
2014>, Ovid OLDMEDLINE(R) <1946 to 1965> 
Search Strategy: 
1 exp Keratoconus/(3681) 
2 keratoconu*.mp. (4770) 
3 keratoconi*.mp. (517) 
4 cornea* ectasia*.mp. (378) 
5 iatrogenic cornea*.mp. (17) 
6 exp Iatrogenic Disease/(13521) 
7 exp Corneal Diseases/(41837) 
8 6 and 7 (117) 
9 keratectasia*.mp. (192) 
10 1 or 2 or 3 or 4 or 5 or 8 or 9 (5150) 
11 ((intracornea* or intra-cornea* or intrastroma* or intra-stroma*) adj5 ring*).mp. (404) 
12 ICRS.mp. (557) 
13 ferrara ring*.mp. (16) 
14 intacs.mp. (197) 
15 (cornea* adj5 implant*).mp. (1154) 
16 Addition Technolog*.mp. (93) 
17 Keraring*.mp. (44) 
18 Mediphacos.mp. (23) 
19 Bisantis.mp. (0) 
20 Optikon.mp. (32) 
21 *Eye, Artificial/(961) 
22 *"Prostheses and Implants"/(26657) 
23 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 20 or 21 or 22 (29023) 
24 10 and 23 (345) 
25 exp Clinical Trial/or double-blind method/or (clinical trial* or randomized controlled trial or 
multicenter study).pt. or exp Clinical Trials as Topic/or ((randomi?ed adj7 trial*) or (controlled 
adj3 trial*) or (clinical adj2 trial*) or ((single or doubl* or tripl* or treb*) and (blind* or 
mask*))).ti,ab. (1246098) 
26 ((systematic adj3 literature) or systematic review* or meta-analy* or metaanaly* or "research 
synthesis" or ((information or data) adj3 synthesis) or (data adj2 extract*)).ti,ab. or (cinahl or 
(cochrane adj3 trial*) or embase or medline or psyclit or (psycinfo not "psycinfo database") or 
pubmed or scopus or "sociological abstracts" or "web of science").ab. or "cochrane database of 
systematic reviews".jn. or ((review adj5 (rationale or evidence)).ti,ab. and review.pt.) or meta-
analysis as topic/or Meta-Analysis.pt. or review.pt. (2093955) 
27 25 or 26 (3130953) 
28 24 and 27 (77) 
29 remove duplicates from 28 (73) 
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EMBASE 
No. Query Results Results Date 
#24 intracornea* OR 'intra-cornea' OR 'intra-corneal' OR intrastroma* OR 
'intra-stroma' OR 'intra-stromal') NEAR/5 ring* OR (icrs NOT knee*) 
OR ferrara:dn OR intacs OR cornea* NEAR/5 implant* OR 'addition 
technology' OR 'addition technologies' OR keraring* OR mediphacos 
OR bisantis OR optikon OR 'visual prosthesis'/mj AND ([cochrane 
review]/lim OR [systematic review]/lim OR [controlled clinical 
trial]/lim OR [randomized controlled trial]/lim OR [meta analysis]/lim) 
111 29 Dec 2014 
#22 (intracornea* OR 'intra-cornea' OR 'intra-corneal' OR intrastroma* 
OR 'intra-stroma' OR 'intra-stromal') NEAR/5 ring* OR (icrs NOT 
knee*) OR ferrara:dn OR intacs OR cornea* NEAR/5 implant* OR 
'addition technology' OR 'addition technologies' OR keraring* OR 
mediphacos OR bisantis OR optikon OR 'visual prosthesis'/mj 
3,484 29 Dec 2014 
#21 'visual prosthesis'/mj 1,085 29 Dec 2014 
#20 optikon 94 29 Dec 2014 
#19 bisantis 45 29 Dec 2014 
#18 mediphacos 54 29 Dec 2014 
#17 keraring* 56 29 Dec 2014 
#16 'addition technologies' 16 29 Dec 2014 
#15 'addition technology' 121 29 Dec 2014 
#14 cornea* NEAR/5 implant* 1,568 29 Dec 2014 
#13 intacs 247 29 Dec 2014 
#12 ferrara:dn 16 29 Dec 2014 
#11 icrs NOT knee* 512 29 Dec 2014 
#10 (intracornea* OR 'intra-cornea' OR 'intra-corneal' OR intrastroma* 
OR 'intra-stroma' OR 'intra-stromal') NEAR/5 ring* 
464 29 Dec 2014 
#5 iatrogenic NEAR/1 cornea* 27 29 Dec 2014 
#4 cornea* NEAR/1 ectasia*   452 29 Dec 2014 
#3 keratoconi* 522 29 Dec 2014 
#2 keratoconu* 5,717 29 Dec 2014 




Intrastromal corneal implants for ectatic corneal disorders 
60 LBI-HTA | 2015 
Cochrane Library 
Search Name: ICRS for Keratoconus 
Last Saved: 29/12/2014 23:17:51.127 
ID Search 
#1 MeSH descriptor: [Keratoconus] explode all trees 
#2 keratoconu* (Word variations have been searched) 
#3 keratoconi* (Word variations have been searched) 
#4 cornea* near ectasia* (Word variations have been searched) 
#5 iatrogenic cornea* (Word variations have been searched) 
#6 MeSH descriptor: [Iatrogenic Disease] explode all trees 
#7 MeSH descriptor: [Corneal Diseases] explode all trees 
#8 #6 and #7  
#9 keratectasia* (Word variations have been searched) 
#10 #1 or #2 or #3 or #4 or #5 or #8 or #9  
#11 (intracornea* or intra-cornea* or intrastroma* or intra-stroma*) near ring* (Word variations 
have been searched) 
#12 ICRS (Word variations have been searched) 
#13 ferrara* near ring* (Word variations have been searched) 
#14 intacs (Word variations have been searched) 
#15 cornea* near implant* (Word variations have been searched) 
#16 "Addition Technology" (Word variations have been searched) 
#17 Keraring* (Word variations have been searched) 
#18 Mediphacos (Word variations have been searched) 
#19 Bisantis (Word variations have been searched) 
#20 Optikon (Word variations have been searched) 
#21 MeSH descriptor: [Eye, Artificial] explode all trees 
#22 MeSH descriptor: [Prostheses and Implants] this term only 
#23 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22  




CRD (DARE-NHS EED-HTA) 
#### ICRS for Keratoconus 
1 MeSH DESCRIPTOR Keratoconus EXPLODE ALL TREES 
2 (keratocon*) 
3 (cornea* NEAR ectasia*) 
4 (iatrogeniccornea*) 
5 (keratectasia*) 



















Source Trial ID Title Recruitment 
Study 







ClinicalTrials.gov NCT01869517 Myoring Versus Keraring Implantation for 
Keratoconus 
Recruiting No Results 
Available 
May 2013 n/a 23 RCT 
ClinicalTrials.gov NCT00347230 Intacs for Keratoconus Recruiting No Results 
Available 
October 2005 n/a 20 Single-arm 
study 
ClinicalTrials.gov NCT01261013 Intrastromal Corneal Ring Segment Implantation 
in 219 Keratoconic Eyes at Different Stages 
Completed No Results 
Available 
January 2008 March 2010 219 Single-arm 
study 
ClinicalTrials.gov NCT00832897 Evaluation of Topical Riboflavin Exposed to UVA 
Radiation and Implantation of Corneal Ring 
Completed No Results 
Available 
March 2008 October 2010 31 RCT 
ClinicalTrials.gov NCT01112072 Corneal Collagen Crosslinking and Intacs for 
Keratoconus and Ectasia 
Recruiting No Results 
Available 





Comparison of two types of rings in treatment  
of keratoconus 
Recruiting n/a April 2014 n/a 76 RCT 
 
 
 
 
